Cargando…

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

INTRODUCTION: The aim of this investigation was to assess the effect of galantamine, an acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, on brain atrophy in individuals with mild cognitive impairment (MCI), and to assess effect modification by apolipoprotein E (APOE) g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prins, Niels D, van der Flier, Wiesje A, Knol, Dirk L, Fox, Nick C, Brashear, H Robert, Nye, Jeffrey S, Barkhof, Frederik, Scheltens, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255389/ https://www.ncbi.nlm.nih.gov/pubmed/25478019 http://dx.doi.org/10.1186/alzrt275

Ejemplares similares

Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI
por: Leijenaar, Jolien F., et al.
Publicado: (2020)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Visual assessment of posterior atrophy development of a MRI rating scale
por: Koedam, Esther L. G. E., et al.
Publicado: (2011)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Small vessel disease lesion type and brain atrophy: The role of co‐occurring amyloid
por: Heinen, Rutger, et al.
Publicado: (2020)

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
por: Hager, Klaus, et al.
Publicado: (2016)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease
por: Sluimer, Jasper D., et al.
Publicado: (2009)

Microbleeds are associated with depressive symptoms in Alzheimer's disease
por: Leeuwis, Anna E., et al.
Publicado: (2017)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2017)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer’s Disease
por: Kavanagh, S, et al.
Publicado: (2011)

Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease
por: Benedictus, Marije R., et al.
Publicado: (2016)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial
por: Leijenaar, Jolien Fleur, et al.
Publicado: (2018)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Mild cognitive disorder and depression: treatment with combination of galantamine and escitalopram
por: Zarra, Julio, et al.
Publicado: (2010)

Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis
por: Harper, Lorna, et al.
Publicado: (2017)

Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease
por: Lehmann, Manja, et al.
Publicado: (2012)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline
por: Verfaillie, Sander C. J., et al.
Publicado: (2018)

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
por: Zarra, Julio, et al.
Publicado: (2010)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study
por: Boomsma, Jooske MF, et al.
Publicado: (2022)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study
por: Möller, Christiane, et al.
Publicado: (2015)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI
por: Leijenaar, Jolene F, et al.
Publicado: (2022)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the “Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment” (TRACE-VCI) Study
por: Boomsma, Jooske Marije Funke, et al.
Publicado: (2017)

Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia
por: van Straaten, Elisabeth CW, et al.
Publicado: (2012)

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review
por: de Wilde, Arno, et al.
Publicado: (2018)

Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship
por: van Loenhoud, Anna Catharina, et al.
Publicado: (2019)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

An algorithmic approach to structural imaging in dementia
por: Harper, Lorna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o0ofuluog7l6b0g0uk5oa1ctjv